Smith+Nephew Academy Singapore opens, bringing medical education and digital innovation to healthcare professionals across Asia-Pacific
LONDON, Nov. 9, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the opening of Smith+Nephew (S+N) Academy Singapore, a major medical education and digital innovation centre covering the Asia-Pacific region today, in the presence of Mr Gan Kim Yong, Minister for Trade and Industry Singapore, Mr Alex Bamford, Deputy...
NEC Thailand conducts POC for elderly care in preparation for an aging society
BANGKOK, Nov. 9, 2022 /PRNewswire/ -- NEC Corporation (Thailand) Ltd. (NEC Thailand) has conducted a POC for elderly care in preparation for an aging society. The POC features a range of technological solutions designed to improve elderly care across Asia. The announcement follows a successful month-long trial in June at an elderly care...
TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with...
INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept Pharmaceuticals INT-787 has shown strong anti-fibrotic and anti-inflammatory effects in animal models TES Pharma is dedicated to the identification of novel therapeutic targets and the discovery and development of new molecules to efficiently address the needs...
ScoliCare Opens its First Clinic in the US
New service will treat scoliosis and hyperkyphosis patients in Florida NAPLES, Fla. , Nov. 8, 2022 /PRNewswire/ -- ScoliCare, Australia's largest provider of non-surgical scoliosis and hyperkyphosis treatment and leading worldwide brace manufacturer (ScoliBrace®), today announced the opening of its first clinic in the United States. ScoliCare Naples Florida is located at 6291 Naples Blvd, Naples, Florida. To see case studies...
Himalaya Therapeutics Announces Highlights of Recent Clinical Progress
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with additional patients enrolled HTBA3011 Undifferentiated Pleomorphic Sarcoma (UPS) enrollment in Phase 2 part 2 of study anticipated to begin by year-end CAB-CTLA-4 (HTBA3071) Phase 1 study ongoing in tumor types responsive to CTLA-4 inhibition...
Amorepacific publishes its findings on dietary restrictions and lifespan extension in Nature Communications
Discovered the effects of the essential amino acid, threonine, on promoting both life and healthspans. Research findings will be applied to product development of its brand, VITAL BEAUTIE. SEOUL, South Korea, Nov. 8, 2022 /PRNewswire/ -- Amorepacific discovered a mechanism of dietary restriction for lifespan extension in the essential amino...
Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion
Agreement includes aggregate upfront and target nomination fees of up to $21.5 million for up to 6 targets, and additional R&D and sales milestones plus tier-based mid-single- to low double-digit royalties. New York , Nov. 8, 2022 /PRNewswire/ -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research collaboration with Sanofi. Under...
XJTLU and University of Liverpool to inaugurate Joint Centre for Pharmacology and Therapeutics
SUZHOU, China, Nov. 8, 2022 /PRNewswire/ -- On 11 November, Xi'an Jiaotong-Liverpool University (XJTLU) and the University of Liverpool will inaugurate their Joint Centre for Pharmacology and Therapeutics at an online/onsite event in Suzhou, China. Xi'an Jiaotong-Liverpool University (XJTLU) researchers conduct world-class biopharmaceutical research at the University's Suzhou Industrial Park (SIP) campus. XJTLU and...
Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
The Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary Novavax' prototype vaccine induced broad immune response against original Wuhan, BA.1, and BA.5 strains The trial showed no benefit for a bivalent vaccine utilizing Novavax' recombinant protein/adjuvant technology GAITHERSBURG,...
Ascom Applauded by Frost & Sullivan for Improving Hospital Medical Device Workflows with Its MDI Platform
The Medical Device Integration Platform visualizes data and events from medical devices on dashboards and sends actionable insights and alarms to caregivers, supporting their activities while on the move. SAN ANTONIO, Nov. 8, 2022 /PRNewswire/ -- Frost & Sullivan recently analyzed the global medical devices connectivity industry and, based on its research findings,...
